Advertisement

Molecular and Cellular Biochemistry

, Volume 387, Issue 1–2, pp 1–8 | Cite as

RNA interference against MDM2 suppresses tumor growth and metastasis in pancreatic carcinoma SW1990HM cells

  • Weidong Shi
  • Zhiqiang Meng
  • Zhen Chen
  • Yongqiang Hua
  • Huifeng Gao
  • Peng Wang
  • Junhua Lin
  • Zhenhua Zhou
  • Jianmin Luo
  • Luming Liu
Article

Abstract

In our previous study, the mouse double minute 2 (MDM2) was identified as one of the leading genes that promote the metastasis of pancreatic cancer (PC). However, the mechanism by which MDM2 promotes metastasis of PC is not understood. In this study, we show that down-regulation of MDM2 through lentivirus-mediated RNA interference could also suppress in vitro proliferation and in vivo tumor growth, and led to an obvious inhibition of both in vitro invasion and in vivo live metastases of SW1990HM cells which had an over-expression of MDM2 and a higher metastatic potential. Moreover, we also show that the down-regulation of MDM2 induced a significant decrease in MMP9, Ki-67 and increase in P53, E-Cadherin expression, and results in an altered expression of genes involved in metastasis, apoptosis, and cell proliferation. Our results suggest that MDM2 plays an important role in metastasis as well as tumor growth of PC. MDM2 could be a hopeful target for the control of PC.

Keywords

Pancreatic cancer Cell line MDM2 RNA interference Liver metastasis 

Notes

Acknowledgments

The authors thank Jianming Luo, Department of Breast Surgery, of the Breast Cancer Institute, Fudan University, for their help with this study. We also thank Lixin Chen for his help with the animal experiments.

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao YP, Xu JQ, Thun MJ (2010) Cancer Statistics, 2010. CA Cancer J Clin 59:225–249CrossRefGoogle Scholar
  2. 2.
    Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nat Rev Cancer 2(12):897–909PubMedCrossRefGoogle Scholar
  3. 3.
    Momand J, Zambetti GP (1997) Mdm-2: ‘big brother’ of p53. J Cell Biochem 64:343–352PubMedCrossRefGoogle Scholar
  4. 4.
    Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691–694PubMedCrossRefGoogle Scholar
  5. 5.
    Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694–698PubMedCrossRefGoogle Scholar
  6. 6.
    Brown DR, Thomas CA, Deb SP (1998) The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 17:2513–2525PubMedCrossRefGoogle Scholar
  7. 7.
    Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che MX, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A (2009) MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92–02. J Clin Oncol 27:3177–3184PubMedCrossRefGoogle Scholar
  8. 8.
    Noon AP, Vlatkovic′ N, Polan′ski R, Maguire M, Shawki H, Parsons K, Boyd MT (2010) P53 and MDM2 in renal cell carcinoma. Cancer 116:780–790PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP (2009) Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med 7:110PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman DA, Mayo LD (2010) TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest 120:290–302PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Cin PD, Maestro R, Fletcher CD, Tallini G (2000) Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 190:531–536CrossRefGoogle Scholar
  12. 12.
    Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53(1):16–18PubMedGoogle Scholar
  13. 13.
    Zietz C, Rossle M, Haas C, Sendelhofert A, Hirschmann A, Sturzl M, Lohrs U (1998) MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 153:1425–1433PubMedCrossRefGoogle Scholar
  14. 14.
    Zhang L, Hill RP (2004) Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 64:4180–4189PubMedCrossRefGoogle Scholar
  15. 15.
    Yang JY, Zong CS, Xia WY, Wei YK, Ali-Seyed M, Li Z, Broglio K, Berry DA, Hung MC (2006) MDM2 promotes cell motility and invasiveness by regulating E-Cadherin degradation. Mol Biol 26(19):7269–7282Google Scholar
  16. 16.
    Shi WD, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Liu LM (2009) Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett 283:84–91PubMedCrossRefGoogle Scholar
  17. 17.
    Shi WD, Meng ZQ, Chen Z, Luo JM, Liu LM (2011) Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol Cell Biochem 347:117–125PubMedCrossRefGoogle Scholar
  18. 18.
    Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN (1987) RNA rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47(12):3239–3245PubMedGoogle Scholar
  19. 19.
    Zhou GQ, Zhai Y, Cui Y, Zhang XM, Dong XJ, Yang H, He Y, Yao KT, Zhang HX, Zhi LT, Yuan XY, Qiu W, Zhang XA, Shen Y, Qiang BQ, He FC (2007) MDM2 Promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin Cancer Res 13(9):2627–2633PubMedCrossRefGoogle Scholar
  20. 20.
    Jeczen R, Skomra D, Cybulski M, Schneider-Stock R, Szewczuk W, Roessner A, Rechberger T, Semczuk A (2007) P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin Exp Metastasis 24:503–511PubMedCrossRefGoogle Scholar
  21. 21.
    Wang JB, Zheng TS, Chen X, Song XA, Meng XZ, Bhatta N, Pan SH, Jiang HC, Liu LX (2011) MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro. J Gastroenterol Hepatol 26:371–377PubMedCrossRefGoogle Scholar
  22. 22.
    Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM (2010) Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets 10:319–331PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Rayburn ER, Ezell SJ, Zhang R (2009) Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem 9(8):882–903PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Weidong Shi
    • 1
  • Zhiqiang Meng
    • 1
  • Zhen Chen
    • 1
  • Yongqiang Hua
    • 1
  • Huifeng Gao
    • 1
  • Peng Wang
    • 1
  • Junhua Lin
    • 1
  • Zhenhua Zhou
    • 1
  • Jianmin Luo
    • 2
  • Luming Liu
    • 1
  1. 1.Department of Integrative Oncology, and Department of OncologyShanghai Medical CollegeShanghaiPeople’s Republic of China
  2. 2.Central Laboratory, Shanghai Cancer CenterFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations